Form 8-K Intra-Cellular Therapies For: Apr 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq poised to lead Wall St after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Intra-Cellular Therapies (ITCI) PT Raised to $96 at Mizuho
April 22, 2024 5:34 AM EDTMizuho analyst Graig Suvannavejh raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $96.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "On the heels of the first Phase 3 data in major depressive disorder/MDD for ITCI's lead asset lumateperone/Caplyta... More
